Publicaciones en las que colabora con José Vivancos Mora (11)

2024

  1. Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke

    iScience, Vol. 27, Núm. 11

2021

  1. Article targeting pro-oxidant iron with deferoxamine as a treatment for ischemic stroke: Safety and optimal dose selection in a randomized clinical trial

    Antioxidants, Vol. 10, Núm. 8

2013

  1. Neuronal excitotoxicity after carotid angioplasty and stent placement procedures

    Radiology, Vol. 268, Núm. 2, pp. 515-520

2011

  1. Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke

    Stroke, Vol. 42, Núm. 10, pp. 2813-2818

2009

  1. Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study

    Journal of Neurology, Vol. 256, Núm. 2, pp. 217-224

2008

  1. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA

    Stroke, Vol. 39, Núm. 7, pp. 2006-2010

2007

  1. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke

    Stroke, Vol. 38, Núm. 1, pp. 90-95

  2. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study

    Stroke, Vol. 38, Núm. 6, pp. 1855-1859

2006

  1. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke

    Journal of Experimental Medicine, Vol. 203, Núm. 3, pp. 711-717

  2. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions

    Cerebrovascular Diseases, Vol. 22, Núm. 2-3, pp. 123-129

  3. Ischemic preconditioning: A novel target for neuroprotective therapy

    Cerebrovascular Diseases, Vol. 21, Núm. SUPPL. 2, pp. 38-47